Literature DB >> 15579027

Multistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model.

Okio Hino1.   

Abstract

Cancer is a heritable disorder of somatic cells. Environment and heredity both contribute to the origin of human cancer. The Eker (Tsc 2 gene mutant) rat model of hereditary renal carcinoma (RC) is an example of a Mendelian dominantly inherited predisposition to a specific cancer in an experimental animal. To the best of our knowledge, this was the first isolation of a Mendelian dominantly predisposing cancer gene in a naturally occurring animal model. Carcinogenesis looks like an opened Japanese fan, because initiated cells growing in several directions will develop into tumors having many gene abnormalities, and this is suggested by the edge of the fan. To search for such genetic alterations, we identified genes (Niban and Erc) that were expressed more abundantly in renal tumors than in the normal kidney.I will review this unique model for the study of multistep renal carcinogenesis and discuss cancer prevention and delay of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579027     DOI: 10.2174/1566524043359692

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  12 in total

1.  The challenge of prognostic markers in pleural mesothelioma.

Authors:  Andrea Imperatori; Massimo Castiglioni; Lorenzo Mortara; Elisa Nardecchia; Nicola Rotolo
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.

Authors:  Takanori Mori; Ken Tajima; Michihiro Hirama; Tadashi Sato; Kenji Kido; Shin-Ichiro Iwakami; Shinichi Sasaki; Akihiko Iwase; Kazu Shiomi; Masahiro Maeda; Okio Hino; Kazuhisa Takahashi
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

Review 3.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

4.  Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors.

Authors:  Kerstin Stemmer; Heidrun Ellinger-Ziegelbauer; Hans-Jürgen Ahr; Daniel R Dietrich
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

5.  Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.

Authors:  Tomoko Hirohashi; Kiyoko Igarashi; Masaaki Abe; Masahiro Maeda; Okio Hino
Journal:  Mol Clin Oncol       Date:  2013-10-02

6.  Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Authors:  Tadashi Sato; Yohei Suzuki; Takanori Mori; Masahiro Maeda; Masaaki Abe; Okio Hino; Kazuhisa Takahashi
Journal:  Cancer Med       Date:  2014-07-10       Impact factor: 4.452

Review 7.  Environmental carcinogenesis - 100th anniversary of creating cancer.

Authors:  Misa Imai; Okio Hino
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

8.  Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer.

Authors:  Shinya Akatsuka; Yoriko Yamashita; Hiroki Ohara; Yu-Ting Liu; Masashi Izumiya; Koichiro Abe; Masako Ochiai; Li Jiang; Hirotaka Nagai; Yasumasa Okazaki; Hideki Murakami; Yoshitaka Sekido; Eri Arai; Yae Kanai; Okio Hino; Takashi Takahashi; Hitoshi Nakagama; Shinya Toyokuni
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.

Authors:  Tomoaki Ito; Kazunori Kajino; Masaaki Abe; Koichi Sato; Hiroshi Maekawa; Mutsumi Sakurada; Hajime Orita; Ryo Wada; Yoshiaki Kajiyama; Okio Hino
Journal:  Oncol Rep       Date:  2013-10-22       Impact factor: 3.906

10.  The possible roles of B-cell novel protein-1 (BCNP1) in cellular signalling pathways and in cancer.

Authors:  Sapan J Patel; Gaurang L Trivedi; Costel C Darie; Bayard D Clarkson
Journal:  J Cell Mol Med       Date:  2016-09-29       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.